The CCT model is a high-risk, high-reward moonshot in addiction neuroscience, aligning with Emergent Ventures' focus on bold, transformative ideas. Eniola's independent research, provisional patent, and endorsements from top neuroscientists strengthen fit, though the grant's typical emphasis on economics/tech may require a compelling narrative linking neuropharmacology to societal well-being.